Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis.

Rabinovich A, Cohen JM, Cushman M, Kahn SR; BioSOX Investigators..

J Vasc Surg Venous Lymphat Disord. 2015 Oct;3(4):347-53.e1. doi: 10.1016/j.jvsv.2015.04.005. Epub 2015 Aug 1.

PMID:
26992609
2.

Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome.

Rabinovich A, Cohen JM, Cushman M, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Lazo-Langner A, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Ginsberg JS, Kahn SR.

J Thromb Haemost. 2015 Mar;13(3):398-408. doi: 10.1111/jth.12814. Epub 2015 Feb 10.

3.

Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial.

Kahn SR, Shapiro S, Ducruet T, Wells PS, Rodger MA, Kovacs MJ, Anderson D, Tagalakis V, Morrison DR, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Galanaud JP, Ginsberg JS.

Thromb Haemost. 2014 Dec;112(6):1137-41. doi: 10.1160/TH14-05-0430. Epub 2014 Aug 28.

PMID:
25183442
4.

Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.

Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Houweling AH, Ducruet T, Holcroft C, Johri M, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Ginsberg JS; SOX trial investigators..

Lancet. 2014 Mar 8;383(9920):880-8. doi: 10.1016/S0140-6736(13)61902-9. Epub 2013 Dec 6.

PMID:
24315521
5.

Identification of the adenovirus E4orf4 protein binding site on the B55α and Cdc55 regulatory subunits of PP2A: Implications for PP2A function, tumor cell killing and viral replication.

Mui MZ, Kucharski M, Miron MJ, Hur WS, Berghuis AM, Blanchette P, Branton PE.

PLoS Pathog. 2013;9(11):e1003742. doi: 10.1371/journal.ppat.1003742. Epub 2013 Nov 14.

6.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators..

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

7.

Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.

Kahn SR, Springmann V, Schulman S, Martineau J, Stewart JA, Komari N, McLeod A, Strulovitch C, Blostein M, Faucher JP, Gamble G, Gordon W, Kagoma PK, Miron MJ, Laverdière D, Game M, Mills A.

Thromb Haemost. 2012 Sep;108(3):493-8. doi: 10.1160/TH12-03-0169. Epub 2012 Jul 10.

PMID:
22782073
8.

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.

Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE; Cassiopea Investigators..

Lancet. 2012 Jan 14;379(9811):123-9. doi: 10.1016/S0140-6736(11)61505-5. Epub 2011 Nov 28.

PMID:
22130488
9.

Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation.

Guanella R, Ducruet T, Johri M, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Ginsberg JS, Lamping DL, Shrier I, Kahn SR.

J Thromb Haemost. 2011 Dec;9(12):2397-405. doi: 10.1111/j.1538-7836.2011.04516.x.

10.

Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.

Equinox Investigators..

J Thromb Haemost. 2011 Jan;9(1):92-9. doi: 10.1111/j.1538-7836.2010.04100.x.

11.

Relation between D-dimer level, venous valvular reflux and the development of post-thrombotic syndrome after deep vein thrombosis.

Latella J, Desmarais S, Miron MJ, Roussin A, Joyal F, Kassis J, Solymoss S, Desjardins L, Ginsberg JS, Kahn SR.

J Thromb Haemost. 2010 Oct;8(10):2169-75. doi: 10.1111/j.1538-7836.2010.04001.x.

12.

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.

Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study..

Ann Intern Med. 2010 Jul 6;153(1):8-18. doi: 10.7326/0003-4819-153-1-201007060-00004.

PMID:
20621900
13.

The adenovirus E4orf4 protein induces G2/M arrest and cell death by blocking protein phosphatase 2A activity regulated by the B55 subunit.

Li S, Brignole C, Marcellus R, Thirlwell S, Binda O, McQuoid MJ, Ashby D, Chan H, Zhang Z, Miron MJ, Pallas DC, Branton PE.

J Virol. 2009 Sep;83(17):8340-52. doi: 10.1128/JVI.00711-09. Epub 2009 Jun 17.

14.

Localization and importance of the adenovirus E4orf4 protein during lytic infection.

Miron MJ, Blanchette P, Groitl P, Dallaire F, Teodoro JG, Li S, Dobner T, Branton PE.

J Virol. 2009 Feb;83(4):1689-99. doi: 10.1128/JVI.01703-08. Epub 2008 Dec 10.

15.

Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis.

Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS.

Ann Intern Med. 2008 Nov 18;149(10):698-707.

PMID:
19017588
16.

The adenovirus E4orf4 protein induces growth arrest and mitotic catastrophe in H1299 human lung carcinoma cells.

Li S, Szymborski A, Miron MJ, Marcellus R, Binda O, Lavoie JN, Branton PE.

Oncogene. 2009 Jan 22;28(3):390-400. doi: 10.1038/onc.2008.393. Epub 2008 Oct 27.

PMID:
18955965
17.

Determinants of health-related quality of life during the 2 years following deep vein thrombosis.

Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Ginsberg JS.

J Thromb Haemost. 2008 Jul;6(7):1105-12. doi: 10.1111/j.1538-7836.2008.03002.x. Epub 2008 Jun 1.

18.

VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis.

Kahn SR, Lamping DL, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Shrier I; VETO Study investigators..

J Clin Epidemiol. 2006 Oct;59(10):1049-56. Epub 2006 Jun 23. Erratum in: J Clin Epidemiol. 2006 Dec;59(12):1334.

PMID:
16980144
19.

Prospective evaluation of health-related quality of life in patients with deep venous thrombosis.

Kahn SR, Ducruet T, Lamping DL, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Shrier I.

Arch Intern Med. 2005 May 23;165(10):1173-8.

PMID:
15911732
20.

Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death.

Miron MJ, Gallouzi IE, Lavoie JN, Branton PE.

Oncogene. 2004 Sep 30;23(45):7458-68. Erratum in: Oncogene. 2005 Jun 9;24(25):4162.

PMID:
15334069

Supplemental Content

Loading ...
Support Center